Have a HbA1c value between ≥ 6.5% and ≤ 9.5% at screening
Are on stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening
Have an increased risk of cardiovascular events
Have a BMI ≥ 25.0 kg/m2 at screening
Have a stable body weight (\<5% body weight change) for 90 days prior to screening
Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight
You may not be if
Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
Have type 1 diabetes
Have a history or diagnosis of New York Heart Association Functional Classification IV congestive heart failure
Have had within 60 days prior to screening:
* acute myocardial infarction
* stroke
* hospitalization for congestive heart failure, or
* coronary, peripheral, or carotid artery revascularization procedure
Have received treatment combining sulfonylurea and insulin within 90 days prior to screening
Clareo Health | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
